RVL Pharmaceuticals PLC

RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities

RVL Completes Financial Restructuring

RVL Pharmaceuticals (NASDAQ: RVLP ) stock is rising higher on Wednesday even without any news from the specialty pharmaceutical company. Shares of RVL Pharmaceuticals stock are climbing today despite the company not putting out any new press releases.

Why Is RVL Pharmaceuticals (RVLP) Stock Up 40% Today?

Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (“RVL” or “the Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults, today announced that certain of its U.S. operating subsidiaries, RevitaLid Pharmaceutical Corp., RVL Pharmaceuticals, Inc. and RVL Pharmacy, LLC (the “RVL Subsidiaries”), have reached an agreement with their sole secured lenders, funds managed by Athyrium Capital Management (“Athyrium”), and other key stakeholders, to effectuate a change of control transaction through prepackaged bankruptcy cases commenced in the United States Bankruptcy Court for the District of Delaware today (the “Reorganization”).

RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries

RVL Pharmaceuticals (NASDAQ: RVLP ) stock is climbing higher on Friday despite a lack of news from the specialty pharmaceutical company. There aren't any new press releases of filings with the Securities and Exchange Commission (SEC) that explain why the shares are up today.

Why Is RVL Pharmaceuticals (RVLP) Stock Up 28% Today?

BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25 th Annual Global Investment Conference in New York City as follows:

RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.4212 per ordinary share (or ordinary share equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed to issue to the investors unregistered series A-1 warrants to purchase up to 11,870,846 ordinary shares and unregistered series A-2 warrants to purchase up to 11,870,846 ordinary shares. The series A-1 warrants have an exercise price of $0.4212 per share, will be exercisable beginning on the effective date of shareholder approval of the issuance of the shares upon exercise of the series A-1 warrants, and will expire five years following the date of shareholder approval. The series A-2 warrants have an exercise price of $0.4212 per share, will be exercisable beginning on the effective date of shareholder approval of the issuance of the shares upon exercise of the series A-2 warrants, and will expire eighteen months following the date of shareholder approval. The closing of the offering is expected to occur on or about August 18, 2023, subject to the satisfaction of customary closing conditions.

RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q2 2023 Earnings Conference Call August 14, 2023 8:30 AM ET Company Participants Lisa Wilson - In-Site Communications, IR Brian Markison - Chief Executive Officer James Schaub - Chief Operating Officer Michael DePetris - Principal Accounting Officer Conference Call Participants Douglas Tsao - H.C. Wainright John Vandermosten - Zacks SCR Glen Santangelo - Jefferies Operator Good day, and thank you for standing by.

RVL Pharmaceuticals plc (RVLP) Q2 2023 Earnings Call Transcript

-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth --

RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review

-- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET -- -- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET --

RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update

BRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company organized in Ireland focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids, in adults, today announced that, as authorized by the Board of Directors, the Company has been considering certain strategic alternatives. These include discussions to acquire a specific potential counterparty in an all stock strategic transaction and discussions with potential financing sources regarding incremental funding for the combined company in the event such a transaction is consummated. This strategic transaction, if consummated, would result in a more diversified aesthetics company with meaningful revenue and synergies. In addition, the Company is in business development discussions with other parties to further enhance the business on a go-forward basis.

RVL Pharmaceuticals plc Provides Business Update

BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover Rules (the “Rules”) at the Company's Annual General Meeting held on June 15, 2023 (the “AGM”).

RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Lisa Wilson - In-Site Communications Brian Markison - Chief Executive Officer James Schaub - Chief Operating Officer Michael DePetris - Principal Accounting Officer Conference Call Participants Louise Chen - Cantor Fitzgerald John Vandermosten - Zacks SCR Michaela Diverio - Barclays Jorge King - H.C. Wainwright Operator Good morning, everyone.

RVL Pharmaceuticals plc (RVLP) Q1 2023 Earnings Call Transcript

-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year --

RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update

BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its first quarter 2023 financial results and provide a commercial update on Thursday, May 11, 2023, before U.S. financial markets open.

RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update

Selected from 10,000 Entrants Selected from 10,000 Entrants

RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q4 2022 Earnings Conference Call March 20, 2023 8:30 AM ET Company Participants Brian Markison - Chief Executive Officer JD Schaub - Chief Operating Officer Mike DePetris - Chief Financial Officer (interim) Lisa Wilson - In-Site Communications Conference Call Participants Louise Chen - Cantor Fitzgerald Douglas Tsao - HC Wainwright Greg Fraser - Truist Securities John Vandermosten - Zack's Unknown Analyst - Barclays Glen Santangelo - Jefferies Operator Good morning everyone. My name is Shelby and I will be your conference Operator.

RVL Pharmaceuticals (RVLP) Q4 2022 Earnings Call Transcript

-- RVLP records exceptional year-over-year growth with UPNEEQ ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, over 2021 --

RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update

Conference call to be held Monday, March 20, 2023, at 8:30 a.m. ET Conference call to be held Monday, March 20, 2023, at 8:30 a.m. ET

RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial Update

-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for full year 2022 -- -- Approximately 4,300 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the fourth quarter 2022, a 23% increase from the end of the third quarter 2022 --

RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales

Today we take our first look at RVL Pharmaceuticals plc, a small ocular-focused concern. RVL Pharmaceuticals plc recently launched the first and only FDA-approved ophthalmic solution to treat low-lying eyelids in adults.

RVL Pharmaceuticals: A First 'Look'

BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a panel presentation and host 1x1 investor meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference in Miami, FL, as follows:

RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

RVL Pharmaceuticals plc (NASDAQ:RVLP ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lisa Wilson – Investor Relations Brian Markison – Chief Executive Officer JD Schaub – Chief Operating Officer Mike DePetris – Interim Chief Financial Officer Conference Call Participants Louise Chen – Cantor Fitzgerald Douglas Tsao – H.C Wainwright John Vandermosten – Zacks Operator Good day, everyone. My name is Chelsea, and I'll be your conference operator.

RVL Pharmaceuticals plc (RVLP) Q3 2022 Earnings Call Transcript

-- Third quarter 2022 UPNEEQ ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics practices placed orders for UPNEEQ through the end of the third quarter 2022, a 59% increase from the end of the second quarter 2022 --

RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update

--Expects third quarter 2022 preliminary UPNEEQ net product sales of approximately $10.0 million, representing an increase of 19% over the second quarter 2022-- --Third quarter 2022 net product sales growth contributed to approximately $24.4 million in sales for the nine months ended September 30, 2022--

RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product Sales

BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at the H.C. Wainwright 24 th Annual Global Investment Conference as follows:

News for RVL Pharmaceuticals PLC Stock (RVLP)